← Back to patent-cliff list
Angiontensin(1-7)
Tier C — Watch / tradeAngiontensin(1-7)
Tarix Orphan
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Angiotensin II receptor
Indications (approved)：冠状病毒感染, COVID-19, Traumatic brain injury, Ischaemic stroke, 扩张型心肌病, Respiratory insufficiency, Obesity, Hypertension
Regional status
US
Phase III
2021-07-15
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Angiontensin(1-7)?
Approved indications include: 冠状病毒感染, COVID-19, Traumatic brain injury, Ischaemic stroke, 扩张型心肌病, Respiratory insufficiency, Obesity, Hypertension.
When does the Angiontensin(1-7) patent expire?
No public expiry year is available for Angiontensin(1-7) yet; this page updates once verified.
How do I get a quote for Angiontensin(1-7) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06